“…The progressive acquisition of mutations in oncogenes or tumor-suppressor genes might act in concert with epigenetic events, such as functional down-regulation of TIA proteins, to give cells a competitive growth advantage. TIA1 and TIAR genes are mutated [52] and down-regulated [18] , [21] , [25] , [44] , [49] , [50] in several types of human cancers. In human transformed cells, TIA proteins regulate the transcription, alternative splicing, stability and/or translation of many target genes associated with tumor development and progression, involving the control of cell proliferation, apoptosis, angiogenesis, invasion, metastasis, evasion of immune recognition and metabolic reprogramming [13] – [25] .…”